Preparation and evaluation of floating risedronate sodium Gelucire® 39/01 matrices

Acta Pharmaceutica

Volumn 54, Issue 3, 2004, Pages 205-214

  Chauhan, Bhaskar ^a   Shimpi, Shyam ^a   Mahadik, Kakasaheb R ^a   Paradkar, Anant ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Ageing; Gelucire 39 01; Hot stage polarizing microscopy; Risedronate sodium; Scanning electron microscopy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CAPROL PGE 860; EMULSIFYING AGENT; GELATIN; GELUCIRE; GELUCIRE 39 01; GLYCEROL BEHENATE; GLYCEROL DERIVATIVE; GLYCEROL PALMITOSTEARATE; LICAP; NONIONIC SURFACTANT; RISEDRONIC ACID;

ADULT; AGING; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; GAMMA SCINTIGRAPHY; HOT STAGE MICROSCOPY; HUMAN; HUMAN EXPERIMENT; HYDROPHOBICITY; MALE; MICROSCOPY; OSTEOPOROSIS; PAGET BONE DISEASE; POLARIZATION MICROSCOPE; SCANNING ELECTRON MICROSCOPY; STOMACH MUCOSA; SUSTAINED RELEASE PREPARATION; TEMPERATURE;

EID: 6344279791     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. H. Fleisch, Bisphosphonates: preclinical aspects and use in osteoporosis, Ann, Med. 29 (1997) 55-62.
2. P. D. Delmas and P. J. Meunier, The management of Paget's disease of bone, N. Engl. J. Med. 336 (1997) 558-566.
3. A. Johansen, M. Stone and F. Rawlinson, Bisphosphonates and the treatment of bone disease in the elderly, Drugs Aging 8 (1996) 113-126.
4. A. Ezra and G. Golomb, Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption, Adv. Drug Del. Rev. 42 (2000) 175-195.
5. I. M. Twiss, R. De Water, J. Den Hartigh, J. R. Sparidans, W. Ramp-Koopmanschap, H. Brill, M. Wijdeveld and P. Vermeij, Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport, J. Pharm. Sci. 83 (1994) 699-703.
6. J. H. Lin, Bisphosphonates: A review of their pharmacokinetic properties, Bone 18 (1996) 75-85.
7. R. Niemi, J. Vepsalainen, H. Taipale and T. Jarvinen, Bisphonates prodrugs: synthesis and an in vitro evaluation of novel acyloxylated esters of clodronic acid, J. Med. Chem. 42 (1999) 5053-5085.
8. R. Niemi, J. Vepsalainen, H. Taipale and T. Jarvinen, Bisphosphonates prodrugs: synthesis and in vitro evaluation of alkyl and acyloxy esters of etidronic acid as bioreversible prodrugs of etidronate, Eur. J. Pharm. Sci. 11 (2000) 173-180.
9. X. Boulenc, T. Breul, J. C. Gautier, P. Saudemon, H. Joyeux, C. Roques, Y. Berger and G. Fabre, Sodium lauryl sulphate increases tiludronate paracellular transport using epithelial Caco-2 monolayers, Int. J. Pharm. 123 (1995) 71-83.
10. T. Lindmark, Y. Kimura and P. Artursson, Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells, J. Pharmacol. Exp. Ther. 284 (1998) 362-369.
11. J. Raiman, S. Törmälehto, K. Yritys, H. E. Junginger and J. Mönkkönen, Effect of various absorption enhancer on transport of clodronate through Caco-2 cells, Int. J. Pharm. 261 (2003) 129-136.
12. M. Flashner-Barak, V. Rosenberger, M. Dahan and Y. Lerner, Composition and Dosage Form for Delayed Gastric Release of Alendronate and/or Other Bis-phosphonates, WO 2002000204, 3 Jan 2002, ref. Chem. Abstr. 136 (2002) 74647g.
13. C. J. H. Porter and W. N. Charman, In vitro assessment of oral lipid based formulations, Adv. Drug Del. Rev. 50 (2001) S127-S147.
14. W. Bowtle, Lipid formulations for oral drug delivery, Pharm. Technol. Eur. 12 (2000) 20-30.
15. K. Kumar, M. H. Shah, A. Ketkar, K. R. Mahadik and A. Paradkar, Effect of drug solubility and different excipients on floating behavior and release from glyceryl mono-oleate matrices, Int. J. Pharm. 272 (2004) 151-160.
16. N. Ahlgren, J. Cascone, J. Fitzpatrick, S. E. Frisbee, J. Getz, M. R. Herman, B. M. Kiernan, O. E. Barbara, D. Pereira and P. P. Sanghvi, Fatty Ester Combinations, U.S. Pat. 6,117,452, 12 Sep 2000; ref. Chem. Abstr. 132 (2000) 171153a.
17. C. W. Pouton, Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification, Int. J. Pharm. 27 (1985) 335-348.
18. A. Aïnaoui and J. M. Vergnaud, Modelling the plasma drug level with oral sustained release forms with lipidic gelucire, Int. J. Pharm. 169 (1998) 155-162.
19. W. Sutananta, D. Q. M. Craig and J. M. Newton, The effects of ageing on the thermal behaviour and mechanical properties of pharmaceutical glycerides, Int. J. Pharm. 111 (1994) 51-62.
20. A. Aïnaoui, E. M. Ouriemchi, D. Bidah, M. K. El Amrani and J. M. Vergnaud, Process of drug release with oral dosage forms with lipidic gelucire matrix, J. Polymer Eng. 17 (1997) 245-257.
21. A. B. Dennis, S. J. Farr, I. W. Kellaway, G. Taylor and R. Davidson, In vivo evaluation of rapid release and sustained release gelucire capsule formulation, Int. J. Pharm. 65 (1990) 85-100.
22. The United States Pharmacopoeia 24, United States Pharmacopoeial Convention, Rockville 2000.
23. V. Iannuccelli, G. Coppi, M. T. Bernabei and R. Cameroni, Air compartment multiple-unit system for prolonged gastric residence. Part I. Formulation study, Int. J. Pharm. 174 (1998) 47-54.
24. T. Lindmark, Y. Kimura and P. Artursson, Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells, J. Pharmacol. Exp. Ther. 284 (1998) 362-369.